KalVista Pharmaceuticals Inc. (KALV) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Comparison side by side

As Biotechnology companies, KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
KalVista Pharmaceuticals Inc. 18.04M 27.64 12.95M -1.23 0.00
ANI Pharmaceuticals Inc. 201.58M 3.73 15.34M 1.18 54.82

Table 1 demonstrates KalVista Pharmaceuticals Inc. and ANI Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 represents KalVista Pharmaceuticals Inc. (NASDAQ:KALV) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
KalVista Pharmaceuticals Inc. -71.78% -30.1% -17.9%
ANI Pharmaceuticals Inc. 7.61% 0.1% 0%

Volatility & Risk

KalVista Pharmaceuticals Inc.’s current beta is 2.46 and it happens to be 146.00% more volatile than S&P 500. ANI Pharmaceuticals Inc.’s 2.41 beta is the reason why it is 141.00% more volatile than S&P 500.


6.2 and 6.2 are the respective Current Ratio and a Quick Ratio of KalVista Pharmaceuticals Inc. Its rival ANI Pharmaceuticals Inc.’s Current and Quick Ratios are 3.3 and 2.5 respectively. KalVista Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than ANI Pharmaceuticals Inc.

Analyst Recommendations

KalVista Pharmaceuticals Inc. and ANI Pharmaceuticals Inc. Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
KalVista Pharmaceuticals Inc. 0 0 0 0.00
ANI Pharmaceuticals Inc. 0 0 3 3.00

Competitively the average target price of ANI Pharmaceuticals Inc. is $75.67, which is potential 19.18% upside.

Institutional & Insider Ownership

Roughly 82.2% of KalVista Pharmaceuticals Inc. shares are owned by institutional investors while 81.8% of ANI Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 2.9% of KalVista Pharmaceuticals Inc. shares. Insiders Competitively, owned 2.1% of ANI Pharmaceuticals Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
KalVista Pharmaceuticals Inc. 2.29% 21.99% -0.57% 39.88% 120.29% 15.44%
ANI Pharmaceuticals Inc. 6.15% 20.06% 15.86% 11.7% 5.74% 43.31%

For the past year KalVista Pharmaceuticals Inc. was less bullish than ANI Pharmaceuticals Inc.


On 10 of the 12 factors ANI Pharmaceuticals Inc. beats KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companyÂ’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.